US Politicians Are Buying These Two Stocks

Boston Scientific shares declined after Citigroup downgraded the stock to 'Neutral' from 'Buy' and lowered its price target to $50 from $57. The company's shares are currently trading at $43.20, down 1.62% on the day but up 0.61% year-to-date, according to Citigroup.

Citigroup downgraded Boston Scientific to 'Neutral' from 'Buy' and lowered its price target to $50 from $57. The stock closed at $43.91, up 0.09%.

Accenture agreed to pay $25 million to settle U.S. DOJ allegations of discrimination in hiring, promotion, and professional development through its DEI programs. The settlement is part of the DOJ's Civil Rights Fraud Initiative. Accenture denies liability but aims to avoid prolonged litigation. The DOJ claims Accenture considered race or sex in decisions and tracked progress towards workforce composition goals.

Accenture (ACN) stock fell 22% over the past year, despite revenue growth of 6.7% and a 15.8% operating margin. The company is expanding into new markets and making acquisitions, but its stock performance lags peers like IBM (IBM) and Booz Allen Hamilton (BAH). Accenture's guidance for fiscal 2026 includes 3-4% revenue growth, partly driven by acquisitions.

Accenture will pay $25 million to settle U.S. Justice Department claims it discriminated based on race and sex in hiring and promotions while holding federal contracts. The company denies wrongdoing and says the settlement is not an admission of liability. The Justice Department alleges Accenture used demographic targets and separate review processes for promotions. Accenture's federal contracts have also faced recent cuts by the Pentagon.

Accenture agreed to pay $25 million to settle DOJ allegations of discrimination in hiring and promotions from 2017 to 2026, joining IBM ($17M) and Deloitte ($21.5M) in settlements under Trump's Civil Rights Fraud Initiative. All deny liability. The total payouts reach $63.5 million.